Tiago Marques bought KTTA once, on Nov 28, 2025

Tiago Reis Marques, MD, PhD, is a psychiatrist and biotechnology executive serving as Chief Executive Officer of Pasithea Therapeutics Corp. (Nasdaq: KTTA), a U.S.-based company focused on developing novel treatments for psychiatric and neurological disorders.( He has led Pasithea as CEO since 2021, overseeing its strategy in central nervous system drug development and its service offerings providing access to IV ketamine infusions for patients with mental illness.( As CEO, he represents the company in investor and industry forums and has been closely associated with Pasithea’s corporate transactions and clinical development initiatives.(

Marques maintains an active academic and clinical career alongside his corporate leadership. He is a fellow at Imperial College London’s Faculty of Medicine, a lecturer at the Institute of Psychiatry, King’s College London, and a psychiatrist at Maudsley Hospital, one of the world’s leading psychiatry centers.( His research focuses on the mechanisms of action of psychiatric medications and identifying novel therapeutic targets, and he has co‑authored international treatment guidelines and book chapters, including contributions to Neurobiology of Mental Illness, a leading text in the field.( Marques earned his MD from Universidade de Coimbra and his PhD in Medicine from King’s College London, reflecting a career that integrates clinical psychiatry, academic research, and leadership in neuropsychiatric drug development.(

Written by Perplexity from public sources.